This approach revealed concomitant expression of CD44 and SREBP2 in a subset of cells of the invasive area of the tumor (Fig 5D), suggesting that the metastatic progression might require the acquisition of both metabolic and phenotypic features by the cells of the primary tumors. The gene discussed is CD44; the disease is neoplasm.